Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | TGM2 | P21980 | 1/20 | 0.53 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.53 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.53 |
| ▸ | IMPDH2 | P12268 | 6/20 | 0.52 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.52 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.52 |
| ▸ | HINT1 | P49773 | 1/20 | 0.51 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.50 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.49 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.49 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.49 |
| ▸ | KRAS | P01116 | 2/20 | 0.49 |
| ▸ | PNP | P00491 | 1/20 | 0.48 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5334255 | 0.92 | FUT5 (0.58) | NT5EPOLBTGM2FUT5HINT1 | |
| SCHEMBL20442306 | 0.92 | NT5E (0.59) | NT5EPOLBTGM2FUT5HINT1 | |
| SCHEMBL20442307 | 0.90 | POLB (0.61) | NT5EPOLBTGM2TAS1R3TAS1R1 | |
| SCHEMBL2922052 | 0.90 | POLB (0.61) | NT5EPOLBTGM2TAS1R3TAS1R1 | |
| SCHEMBL21636981 | 0.90 | NT5E (0.56) | NT5EPOLBTGM2TAS1R3TAS1R1 | |
| SCHEMBL21636997 | 0.90 | NT5E (0.56) | NT5EPOLBTGM2TAS1R3TAS1R1 | |
| SCHEMBL21417496 | 0.90 | NT5E (0.56) | NT5EPOLBTGM2TAS1R3TAS1R1 | |
| SCHEMBL23760838 | 0.87 | NT5E (0.54) | NT5EPOLBTGM2TAS1R3TAS1R1 | |
| SCHEMBL18158915 | 0.86 | NT5E (0.53) | NT5EPOLBTGM2TAS1R3TAS1R1 | |
| SCHEMBL13134477 | 0.85 | POLB (0.68) | NT5EPOLBTGM2TAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10723756-B2 | Cyclic dinucleotides for treating conditions associated with STING activity such as cancer | INNATE TUMOR IMMUNITY INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-20190031708-A1 | CYCLIC DINUCLEOTIDES FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY SUCH AS CANCER | IFM THERAPEUTICS INC (US) | 2019-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10723756-B2 | Cyclic dinucleotides for treating conditions associated with STING activity such as cancer | STING1, CGAS, IRF3 | NT5E 288/4885POLB 167/4885TGM2 2165/4885 |
| US-20190031708-A1 | CYCLIC DINUCLEOTIDES FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY SUCH AS CANCER | STING1, CGAS, IRF3 | NT5E 196/4885POLB 23/4885TGM2 1124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.